NRx Defense Systems Advances DARPA-Backed Depression Trial
I'm LongbridgeAI, I can summarize articles.NRx Pharmaceuticals announced the formation of NRx Defense Systems, a subsidiary focused on neuroplastic treatments. In July 2026, this unit received notice from DARPA that its SPARC-TMS clinical trial for depression was selected for potential award negotiation. The phase 2/3 study tests robotic-enabled TMS combined with NRX-101 at Harvard McLean Hospital and military facilities. While analysts rate the stock as Buy with a $45 target, TipRanks' AI suggests Neutral due to weak financials despite positive technical momentum.
NRX Pharmaceuticals ( (NRXP) ) just unveiled an announcement.
In April 2026, NRx Pharmaceuticals incorporated NRx Defense Systems, a Florida-based research and development subsidiary focused on neuroplastic treatments that pair D-cycloserine with robotic-enabled Transcranial Magnetic Stimulation under neuro-navigation. The new unit is intended to participate in government and non-governmental research, building on earlier phase I and II work led by the company’s Chief Medical Innovation Officer.
On July 21, 2026, NRx Defense Systems received notice from DARPA’s Defense Sciences Office that its proposed SPARC-TMS clinical trial had been selected for negotiation of a potential award, with no funding commitment yet in place. The phase 2/3 FDA-approved study, listed on clinicaltrials.gov, aims to test robotic-enabled TMS combined with NRX-101 for achieving remission from depression at Harvard McLean Hospital, HOPE Therapeutics clinics, and U.S. military treatment facilities including Walter Reed, potentially strengthening the company’s position in advanced depression therapies if a contract is ultimately awarded.
The most recent analyst rating on (NRXP) stock is a Buy
with a $45.00 price target.
To see the full list of analyst forecasts on NRX Pharmaceuticals stock,
see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
The score is held down primarily by weak financial performance (large losses, heavy cash burn, and negative equity). This is partially offset by constructive technical momentum and a generally positive earnings-call backdrop focused on near-term regulatory/manufacturing milestones and improved reported losses, though funding and execution risks remain material.
To see Spark’s full report on NRXP stock,
click here.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. operates in the biopharmaceutical industry, developing neuropsychiatric treatments that target depression and related disorders. Its portfolio includes NRX-101, a patented combination of D-cycloserine and lurasidone that has previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and it is expanding into neuroplastic therapies through its NRx Defense Systems subsidiary.
Average Trading Volume: 1,186,914
Technical Sentiment Signal: Buy
Current Market Cap: $175.3M
For an in-depth examination of NRXP stock, go to TipRanks’ Overview page.